Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
68
MDGL Quote, Financials, Valuation and Earnings
Last price:
$586.25
Seasonality move
:
22.19%
Day range:
$570.50 - $592.88
52-week range:
$265.00 - $605.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.36x
P/B ratio:
21.05x
Volume:
264.7K
Avg. volume:
400K
1-year change:
80.45%
Market cap:
$13.2B
Revenue:
$180.1M
EPS (TTM):
-$13.01
Analysts' Opinion
-
Consensus RatingMadrigal Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $563.80, Madrigal Pharmaceuticals, Inc. has an estimated downside of -2.78% from its current price of $579.89.
-
Price Target UpsideAccording to analysts, the highest upside price target is $650.00 representing 12.09% upside increase from its current price of $579.89.
Fair Value
-
According to the consensus of 14 analysts, Madrigal Pharmaceuticals, Inc. has -2.78% downside to fair value with a price target of $563.80 per share.
MDGL vs. S&P 500
-
Over the past 5 trading days, Madrigal Pharmaceuticals, Inc. has underperformed the S&P 500 by -2.06% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Madrigal Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Madrigal Pharmaceuticals, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Madrigal Pharmaceuticals, Inc. reported revenues of $287.3M.
Earnings Growth
-
Madrigal Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Madrigal Pharmaceuticals, Inc. reported earnings per share of -$5.08.
Enterprise value:
12.4B
EV / Invested capital:
12.76x
Price / LTM sales:
17.36x
EV / EBIT:
--
EV / Revenue:
16.74x
PEG ratio (5yr expected):
-1.39x
EV / Free cash flow:
-75.33x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$704M
Return On Assets:
-26.33%
Net Income Margin (TTM):
-39.04%
Return On Equity:
-40.56%
Return On Invested Capital:
-32.91%
Operating Margin:
-39.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $76.8M | $740.6M | $62.2M | $287.3M | |
| Gross Profit | -$514K | $73.2M | $704M | $59.7M | $268.8M | |
| Operating Income | -$348.6M | -$548.1M | -$307.5M | -$116.3M | -$114M | |
| EBITDA | -$348.1M | -$547.2M | -$306M | -$116M | -$113.6M | |
| Diluted EPS | -$19.24 | -$25.07 | -$13.01 | -$4.92 | -$5.08 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $303M | $157.1M | $235.5M | $1.1B | $1.3B | |
| Total Assets | $304.7M | $158.6M | $238M | $1.1B | $1.4B | |
| Current Liabilities | $69.3M | $98.9M | $99.7M | $177.8M | $391.4M | |
| Total Liabilities | $69.8M | $148M | $215.7M | $296.1M | $736.7M | |
| Total Equity | $234.9M | $10.7M | $22.2M | $777.2M | $625.7M | |
| Total Debt | $897K | $49.1M | $116.1M | $118.3M | $345.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$302.8M | -$431M | -$160.6M | -$67M | $79.9M | |
| Cash From Investing | -$74M | -$588.6M | -$43.2M | -$202.4M | -$207M | |
| Cash From Financing | $379.5M | $1.2B | $266.8M | $7.5M | $236.6M | |
| Free Cash Flow | -$303.3M | -$438.3M | -$164.6M | -$67.8M | $76M | |
MDGL
Sector
Market Cap
$13.2B
$28.4M
Price % of 52-Week High
95.85%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-0.9%
-1.32%
1-Year Price Total Return
80.45%
-22.19%
Beta (5-Year)
-1.034
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$582.30
200-day SMA
Buy
Level
$369.09
Bollinger Bands (100)
Buy
Level
352.82 - 505
Chaikin Money Flow
Buy
Level
27.2M
20-day SMA
Buy
Level
$546.64
Relative Strength Index (RSI14)
Buy
Level
66.29
ADX Line
Buy
Level
31.65
Williams %R
Neutral
Level
-25.11
50-day SMA
Buy
Level
$478.49
MACD (12, 26)
Buy
Level
34.22
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
7.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.3225)
Sell
CA Score
(Annual)
Level (-2.1807)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (2.2876)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
Stock Forecast FAQ
In the current month, MDGL has received 13 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MDGL average analyst price target in the past 3 months is $563.80.
-
Where Will Madrigal Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Madrigal Pharmaceuticals, Inc. share price will drop to $563.80 per share over the next 12 months.
-
What Do Analysts Say About Madrigal Pharmaceuticals, Inc.?
Analysts are divided on their view about Madrigal Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Madrigal Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to $456.00.
-
What Is Madrigal Pharmaceuticals, Inc.'s Price Target?
The price target for Madrigal Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $563.80 according to 14 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MDGL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Madrigal Pharmaceuticals, Inc. is a Buy. 13 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MDGL?
You can purchase shares of Madrigal Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Madrigal Pharmaceuticals, Inc. shares.
-
What Is The Madrigal Pharmaceuticals, Inc. Share Price Today?
Madrigal Pharmaceuticals, Inc. was last trading at $586.25 per share. This represents the most recent stock quote for Madrigal Pharmaceuticals, Inc.. Yesterday, Madrigal Pharmaceuticals, Inc. closed at $579.89 per share.
-
How To Buy Madrigal Pharmaceuticals, Inc. Stock Online?
In order to purchase Madrigal Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MDGL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MDGL
Sector
P/E ratio
--
23.66x
PEG ratio
-1.39x
-0.01x
P/B ratio
21.05x
1.84x
Price / LTM sales
17.36x
1.60x
Growth Metrics
MDGL
Sector
Revenue growth
362.03%
4.85%
Earnings growth
-3.26%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$1.99
-$0.20
Profitability
MDGL
Sector
Profitability FY 2024
$172.8M
$3.6M
Return on invested capital
-32.91%
-30.98%
Return on assets
-26.33%
-27.62%
Return on equity
-40.56%
-36.69%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
3
Balance Sheet
MDGL
Sector
Total cash
$1.1B
$27.2M
Short term investments
$826.2M
$25.7M
Total assets
$1B
$79.9M
Long term debt
$345.3M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
